Position Paper
The Position Paper series is a compilation of the views of the Policy Research Institute on important topics based on the results of our research to date.
Please refrain from reproducing or reprinting the position papers without permission.
-
Toward the Advancement and Value Enhancement of Medicine and Drugs Co-created with Patients
-Patient-Reported Outcome (PRO) Assessment as a Permanent Part of the Process-
(No. 10: Published December 2025) -
Survey on Domestic Emerging Pharmaceutical Companies (EBPs) with Developed Products
(No. 9: Issued November 2025) -
Survey on EBP-derived drugs in the U.S.
-Biotech vs. small molecule products
(No.8: Published in July 2025) -
Report on Survey of Pharmaceutical Companies on Utilization of Public Databases, etc.
From Policy Research Institute News No.75
(No.7: Issued in July 2025) -
A Study on the Rules for Calculating NHI Drug Prices to Assess the Value of Pharmaceuticals
- A continuation of Position Paper No. 3 "Challenges for the Valuation System in the Context of Changes in the Value of Pharmaceuticals" (No. 6, issued in July 2025)
(No. 6: Issued in Feb. 2025) -
Survey of U.S. EBPs that created small molecule drugs
(No. 5: published December 2024) -
Linking Information for Effective Use of Health and Medical Information
(No. 4: Issued Nov. 2024) -
Challenges for Evaluation Systems in the Transition of the Value that Pharmaceuticals Bring
(No.3: Issued October 2024) -
Understanding the actual situation of drug lag/loss and factor analysis
(No.2: Issued Jul. 2024) -
Development of drug discovery centers centered on top researchers to promote creation of new drugs originating from academia (Under One Roof Cluster)
(No.1: Jul. 2024 issue)